Autophagy-Enhancers to Reduce Sleep Disturbances: A Combined Approach
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 76
- 试验地点
- 1
- 主要终点
- Effects of spermidine supplementation on sleep-related visual-spatial memory as measured by computer-based task
研究概览
简要总结
This clinical trial investigates the effects of spermidine supplementation on sleep quality and sleep-dependent memory consolidation in older adults with Subjective Cognitive Decline (SCD) or Mild Cognitive Impairment (MCI), two populations at increased risk of future cognitive decline and dementia. Impaired sleep has been identified as a modifiable factor contributing to cognitive decline, and interventions targeting sleep architecture could offer therapeutic potential to prevent or slow down this decline.
Spermidine is a naturally occurring polyamine found in foods such as wheat germ and soybeans. It induces autophagy, a cellular degradation and recycling process essential for neuronal maintenance and function. In animal studies, spermidine has been shown to improve memory performance, reduce neuroinflammation, and support mitochondrial health. Preliminary findings from human trials in individuals with SCD or MCI suggest potential cognitive benefits of spermidine, but results are not unequivocal, and the impact on sleep has not been systematically evaluated.
In this randomized, double-blind, placebo-controlled trial, 76 participants aged 55 to 70 years with SCD or MCI will receive either spermidine (6 mg/day) or a placebo for 12 weeks. Sleep will be evaluated using overnight EEG in a controlled laboratory setting, focusing on measures such as slow-wave sleep and sleep spindle activity. Memory performance will be assessed before and after the intervention using standardized neuropsychological testing. Numerical skills will be tested at baseline only to compare SCD and MCI participants with healthy controls.
Blood samples will be collected to quantify metabolic indicators, neurodegeneration-related biomarkers, and autophagy-associated proteins. A control group of 38 cognitively healthy individuals will undergo comparable sleep and cognitive assessments without receiving any supplementation.
The primary objective of the study is to characterize the impact of spermidine on sleep-dependent memory consolidation and to identify associated biological changes relevant to aging and neurodegeneration. The results may inform the development of non-pharmacological strategies aimed at preserving cognitive function in individuals at risk for dementia.
详细描述
Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI) represent early stages along the continuum of cognitive decline preceding dementia. Individuals with SCD report persistent cognitive complaints despite normal performance on standardized cognitive testing, whereas MCI is characterized by objective cognitive impairment that does not yet interfere substantially with activities of daily living. Both conditions are associated with an elevated risk of progression to Alzheimer's disease and other dementias. Disruption of sleep architecture is increasingly implicated in the pathophysiology of neurodegenerative disorders, and early interventions targeting sleep-related mechanisms could help delay further cognitive decline. This clinical trial evaluates the effects of spermidine supplementation on sleep quality and sleep-dependent memory consolidation in older adults with SCD or MCI.
Following an adaptation night and an initial baseline sleep assessment with overnight electroencephalography (EEG), participants will be randomly assigned to either the spermidine or placebo group. The intervention consists of a daily oral dose of 6 mg spermidine (administered as three 2 mg sachets), continued over a 12-week period. The trial employs a randomized, double-blind, placebo-controlled design. Placebo sachets, identical in appearance and taste, contain only microcrystalline cellulose. After the 12-week supplementation period, participants will return for a second overnight EEG assessment.
A healthy control group (n=38), matched for age and sex, will undergo comparable baseline assessments but will not receive any intervention. These data will provide normative reference values for sleep and cognitive parameters.
The primary objective of the study is to assess the impact of spermidine on sleep architecture, measured via overnight polysomnography, with a specific focus on slow-wave sleep and sleep spindle activity, EEG markers associated with sleep-dependent memory consolidation and known to decline with age and neurodegeneration. Secondary outcomes include changes in memory consolidation (assessed using a battery of cognitive tasks that target declarative, procedural, and visuospatial memory domains), as well as numerical skills (tested via e.g., digit-letter-decision task, Berlin Numeracy Test). Testing occurs before and after each EEG night to evaluate overnight consolidation effects. All participants will wear actigraphs prior to both EEG nights to monitor sleep-wake cycles and physical activity.
Additional biological endpoints will examine changes in circulating neuropeptides, insulin-glucose homeostasis, and autophagy-related biomarkers. Blood samples are collected at each EEG session and two weeks after the start of supplementation. Physiological assessments include measurements of inflammatory markers (e.g., interleukin (IL)-6, tumor necrosis factor (TNF-α), neuroprotective factors (e.g., Neuropeptide Y, eukaryotic translation initiation factor 5A (eIF5A) hypusination), and metabolic indicators (e.g., fasting insulin, glucose, and lipid profiles).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 55 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •(SCD participants):
- •Men and women
- •Written consent to participate in the study
- •German at native speaker level
- •Age between 55 and 70 years
- •Subjective Cognitive Decline operationalized as:
- •Subjectively reported decline in cognitive function (particularly memory) despite objectively normal cognitive performance (e.g., WMS-LM)
- •Preservation of functional independence
- •No dementia
- •Inclusion Criteria (MCI patients):
- •Men and women
- •Written consent to participate in the study
- •German at native speaker level
- •Age between 55 and 70 years
- •Mild cognitive impairment (MCI) operationalized as:
- •A change in cognitive abilities reported by the patient, relatives or clinic staff (i.e. historical or observed evidence of deterioration over time)
- •Objective evidence of memory impairment (at least 1.0 Standard Deviation (SD) below the normal range on the Wechsler Logical Memory Scale (WMS-LM)); other cognitive domains may also be affected (i.e. amnestic MCI and amnestic + MCI)
- •Preservation of independence of functional abilities
- •No dementia
排除标准
- •(SCD and MCI participants):
- •Patients who are unable to give informed consent
- •Polyamine intake via dietary supplements and/or participation in corresponding intervention studies
- •Dementia according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV)
- •Any condition that impairs clinical or neuropsychological examination procedures
- •Diabetes mellitus
- •Polycystic ovary syndrome
- •Signs of epilepsy, focal brain lesion or head injury with loss of consciousness or immediate post-injury confusion
- •Previous stroke
- •Severe untreated medical problems or unstable medical condition
- •Current major depressive episode
- •Psychotic disorder
- •Bipolar disorder
- •Current or previous substance abuse
- •Other neurodegenerative disease, e.g. Parkinson's disease
- •Vascular dementia
- •Alcohol abuse
- •Participation in an interventional study in the last 3 months and during the entire study period
- •Sleep disorders
- •Taking medication that primarily affects the central nervous system (e.g. antipsychotics, antidepressants, benzodiazepines or any type of over-the-counter sleep-inducing medication such as valerian; anti-dementia medication)
- •Known intolerances or allergies to wheat germ, gluten or histamine
- •Inclusion criteria (healthy controls):
- •Men and women
- •Written consent to participate in the study
- •German at native speaker level
- •Age between 55 and 70 years
- •Subjective cognitive disorders are denied
- •Exclusion criteria (healthy controls):
- •Subjects who are not able to give informed consent
- •Polyamine intake via dietary supplements and/or participation in corresponding intervention studies
- •Dementia according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV)
- •Mild cognitive impairment (MCI), defined as described above in the patient inclusion criteria
- •Any condition that interferes with clinical or neuropsychological examination procedures
- •Diabetes mellitus
- •Polycystic ovary syndrome
- •Signs of epilepsy, focal brain lesion or head injury with loss of consciousness or immediate post-injury confusion
- •Previous stroke
- •Severe untreated medical problems or unstable medical condition
- •Current major depressive episode
- •Psychotic disorder
- •Bipolar disorder
- •Current or past substance abuse
- •Other neurodegenerative disease, e.g. Parkinson's disease
- •Vascular dementia
- •Alcohol abuse
- •Participation in an interventional study in the last 3 months and during the entire study period
- •Sleep disorders
- •Taking medication that primarily affects the central nervous system (e.g. antipsychotics, antidepressants, benzodiazepines or any type of over-the-counter sleep-inducing medication such as valerian; anti-dementia medication)
研究组 & 干预措施
Healthy elderly controls
baseline comparison, healthy controls are not part of the intervention
Dietary Placebo
干预措施: Dietary Placebo (Dietary Supplement)
Dietary Supplement
干预措施: Spermidine Supplementation (Dietary Supplement)
结局指标
主要结局
Effects of spermidine supplementation on sleep-related visual-spatial memory as measured by computer-based task
时间窗: baseline, 12-week follow-up
The visual-spatial memory task is trained at adaptation night and assessed at baseline and follow-up before and after sleep. After an encoding phase consisting of 60 objects (e.g., photo of a band-aid) placed in front of a background (e.g., photo of a treatment room in a doctor's office), a retrieval phase follows directly after encoding in the evening before bedtime, in which 30 randomly selected images from the total of 60 are tested. Participants should memorize the position of the object placed in front of the background and select the correct position by pressing a button. In the next morning, the remaining 30 images are tested in a recall phase. Task performance is measured by speed (in ms) and hit/false or miss. For the spermidine effect, baseline and follow-up task performances of SCD and MCI participants are compared with each other.
Effects of spermidine supplementation on sleep-related verbal memory as measured by computer-based task
时间窗: baseline, 12-week follow-up
The verbal memory task is trained at adaptation night and assessed at baseline and follow-up before and after sleep. After an encoding phase consisting of 44 word pairs, a retrieval phase follows directly after encoding in the evening before bedtime, in which all word pairs are tested in randomized order. The next morning, all word pairs are tested in a recall phase. Task performance is measured by hit/false or miss. For the spermidine effect, baseline and follow-up task performances of SCD and MCI participants are compared with each other.
Effects of spermidine supplementation on sleep quality as measured by electroencephalography (EEG) mean power spectra
时间窗: baseline, 12-week follow-up
Individual mean power spectra are calculated. Subsequently, the mean power is calculated in the following EEG bands: slow oscillations (0.5-1 Hz), low delta (1-1.5 Hz), delta (1-4 Hz), theta (4-8 Hz), and beta (15-25 Hz). For the spermidine effect, baseline and follow-up EEG data are compared with each other.
Effects of spermidine supplementation on sleep quality as measured by sleep spindle count assessed from EEG
时间窗: baseline, 12-week follow-up
Individual mean power spectra are calculated. Subsequently, the mean power is calculated in the following EEG bands: slow frontal spindle (8-12 Hz), fast parietal spindle (12-15 Hz), and the number of slow frontal and fast parietal discrete spindles are counted. Spindle detection is performed based on an algorithm adopted from previous studies. For the spermidine effect, baseline and follow-up EEG data are compared with each other.
Effects of spermidine supplementation on sleep quality as measured by sleep spindle power assessed from EEG
时间窗: baseline, 12-week follow-up
Individual mean power spectra are calculated. Subsequently, the mean power is calculated in the following EEG bands: slow frontal spindle (8-12 Hz), fast parietal spindle (12-15 Hz). Spindle power is analyzed as a further measure of spindle activity. Spindle detection is performed based on an algorithm adopted from previous studies. For the spermidine effect, baseline and follow-up EEG data are compared with each other.
Effects of spermidine supplementation on sleep-related alertness as measured by computer-based task
时间窗: baseline, 12-week follow-up
The alertness task is trained at adaptation night and assessed at baseline and follow-up before and after sleep. It comprises two runs without and two runs with a prior warning tone. For the spermidine effect, baseline and follow-up task performances of SCD and MCI participants are compared with each other. Task performance is measured by speed (in ms) and hit/false or miss.
次要结局
- Differences in autophagy-related blood markers pre and post spermidine intervention in SCD and MCI as measured by polyamine concentration(baseline, 2 weeks after baseline, 12-week follow-up)
- Differences in sleep quality between SCD or MCI and healthy controls (HC) as measured by electroencephalography (EEG) mean power spectra(baseline data)
- Differences in sleep quality between SCD or MCI and healthy controls (HC) as measured by sleep spindle count assessed from EEG(baseline data)
- Differences in sleep quality between SCD or MCI and healthy controls (HC) as measured by sleep spindle power assessed from EEG(baseline data)
- Differences in autophagy-related blood markers pre and post spermidine intervention in SCD or MCI as measured by eIF5A hypusination(baseline, 2 weeks after baseline, 12-week follow-up)
- Differences in neuropeptide Y blood levels pre and post spermidine intervention in SCD or MCI(baseline, 12-week follow-up)
- Differences in sleep-related alertness between SCD or MCI participants and healthy controls as measured by computer-based task(baseline)
- Differences in sleep-related visual-spatial memory between SCD or MCI participants and healthy controls as measured by computer-based task(baseline)
- Differences in sleep-related verbal memory between SCD or MCI participants and healthy controls as measured by computer-based task(baseline)
- Differences in neuropeptide Y blood levels between SCD or MCI and healthy controls(baseline data)
- Differences in autophagy-related blood markers between SCD or MCI and healthy controls as measured by polyamine concentration(baseline data)
- Differences in autophagy-related blood markers between SCD or MCI and healthy controls as measured by eIF5A hypusination(baseline data)
- Differences in numerical skills between SCD or MCI patients and healthy controls as measured by lexical decision task(assessed at baseline only)
- Differences in numerical skills between SCD or MCI participants and healthy controls as measured by Berlin Numeracy Test(assessed at baseline only)
- Differences in autophagy-related blood markers pre and post spermidine intervention in MCI as measured by polyamine concentration(baseline, 2 weeks after baseline, 12-week follow-up)
- Differences in sleep quality between MCI and healthy controls (HC) as measured by electroencephalography (EEG) mean power spectra(baseline data)
- Differences in sleep quality between MCI and healthy controls (HC) as measured by sleep spindle count assessed from EEG(baseline data)
- Differences in sleep quality between MCI and healthy controls (HC) as measured by sleep spindle power assessed from EEG(baseline data)
- Differences in autophagy-related blood markers pre and post spermidine intervention in MCI as measured by eIF5A hypusination(baseline, 2 weeks after baseline, 12-week follow-up)
- Differences in neuropeptide Y blood levels pre and post spermidine intervention in MCI(baseline, 12-week follow-up)
- Differences in sleep-related alertness between MCI patients and healthy controls as measured by computer-based task(baseline)
- Differences in sleep-related visual-spatial memory between MCI patients and healthy controls as measured by computer-based task(baseline)
- Differences in sleep-related verbal memory between MCI patients and healthy controls as measured by computer-based task(baseline)
- Differences in neuropeptide Y blood levels between MCI and healthy controls(baseline data)
- Differences in autophagy-related blood markers between MCI and healthy controls as measured by polyamine concentration(baseline data)
- Differences in autophagy-related blood markers between MCI and healthy controls as measured by eIF5A hypusination(baseline data)
- Differences in numerical skills between MCI patients and healthy controls as measured by lexical decision task(assessed at baseline only)
- Differences in numerical skills between MCI patients and healthy controls as measured by Berlin Numeracy Test(assessed at baseline only)
研究者
Nina Unger
Prof. Dr. med Agnes Flöel, Head of Department of Neurology
University Medicine Greifswald